NDA
Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing
Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA
Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis
Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance
Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results
Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal